Ứng dụng CD58 và CD81 trong theo dõi bệnh tồn lưu tối thiểu ở người bệnh bạch cầu cấp dòng lympho B bằng kĩ thuật tế bào dòng chảy tại bệnh viện Truyền máu Huyết học=Application of CD58 and CD81 in monitoring minimal residual disease (MRD) in patients with B-cell acute lymphoblastic leukemia (B-all) using flow cytometry at Blood Transfusion Hematology hospital

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Thị Tuệ Ngọc Hoàng, Trường Cửu Mai, Hồng Điệp Nguyễn, Ngọc Sang Nguyễn, Phương Liên Nguyễn, Phước Thọ Trương

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2024

Mô tả vật lý: tr.444-450

Bộ sưu tập: Metadata

ID: 478302

Thêm vào giỏ

Identifying the expression levels of CD58 and CD81 on malignant B-cell precursors (BCPs) at diagnosis and after treatment is a recent application for monitoring minimal residual disease (MRD) in B-cell acute lymphoblastic leukemia (B-ALL). Subjects and methods: Our study was conducted in 138 newly diagnosed B-ALL patients, and MRD was assessed post-induction therapy. Results: The CD58 and CD81 expression rates of BCPs at diagnosis were 100%. The research results revealed that the expression of CD58 and CD81 in malignant BCP populations is consistently high, while differences in expression levels were observed between malignant BCPs and normal/activated BCPs (p<
0.0001). Specifically, CD58 tends to be more strongly 2 times expressed in malignant BCPs compared to normal/activated BCPs, whereas CD81 shows 5 times weaker expression in the malignant BCP population. Additionally, evaluating the mean fluorescence intensity (MFI) – corresponding to antibody density on cell surfaces – highlighted significant differences in MFI for CD58 and CD81 between malignant BCPs and normal/activated BCPs. Conclusions: Notably, using the MFI ratio between CD81 and CD58 (MFI CD81/CD58) ≥ 7.9 effectively identifies normal/activated BCP populations with 100% sensitivity and 98.55% specificity.Xác định mức độ biểu hiện của CD58 và CD81 trên quần thể tế bào B non (Bcell precursors - BCPs) ác tính ở lần chẩn đoán và sau điều trị là một ứng dụng gần đây để theo dõi bệnh tồn lưu tối thiểu (MRD - Minimal Residual Disease) trong Bệnh bạch cầu cấp dòng lympho B (BCCDL-B). Đối tượng và phương pháp: Nghiên cứu mô tả hàng loạt ca được thực hiện ở 138 người bệnh BCCDL-B mới chẩn đoán và được đánh giá MRD sau điều trị tấn công. Kết quả nghiên cứu: Tỷ lệ biểu hiện CD58 và CD81 của quần thể BCPs ác tính ở thời điểm chẩn đoán là 100%
biểu hiện CD58 và CD81 ở quần thể BCPs ác tính mang tính ổn định cao, đồng thời ghi nhận có sự khác biệt về mức độ biểu hiện các dấu ấn này giữa các quần thể: BCPs ác tính và BCPs bình thường/hoạt hóa (p<
0,0001). Cụ thể CD58 thường có biểu hiện mạnh hơn 2 lần ở quần thể BCPs ác tính so với các BCPs bình thường/hoạt hóa, và ngược lại CD81 thường có biểu hiện yếu hơn 5 lần trên quần thể BCPs ác tính. Đồng thời, sử dụng việc đánh giá chỉ số cường độ huỳnh quang trung bình (viết tắt là MFI, tương ứng với mật độ kháng thể gắn với các kháng nguyên trên bề mặt tế bào) cho thấy có sự khác biệt MFI rõ rệt của CD58 và CD81 trên quần thể tế bào ác tính so với quần thể BCPs bình thường/hoạt hóa. Kết luận: Chúng tôi nhận thấy sử dụng tỉ số MFI giữa CD81 và CD58 (ký hiệu: MFI CD81/CD58) ≥ 7,9 sẽ xác định được quần thể BCPs bình thường/hoạt hóa với độ nhạy 100% và độ đặc hiệu 98,55%.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR